Although there is a strong evidence base for pharmacotherapy in COPD, much of this is
based on the use of individual therapies such as long acting bronchodilators (LABA/LAMA) …

Triple therapy for COPD consists of a long-acting anti-cholinergic bronchodilator, a long-
acting beta-agonist bronchodilator, and an inhaled corticosteroid. Guidelines from the …

Combining a long-acting β 2-agonist (LABA) with a long-acting anti-muscarinic agent
(LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have …

Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) bronchodilators
and their combination are recommended for the maintenance treatment of chronic …

Purpose Treatment pathways of patients with chronic obstructive pulmonary disease
(COPD) receiving single-inhaler dual therapies remain unclear. We aimed to describe …

Background Inhaled corticosteroid (ICS)/long-acting β 2 agonist (LABA) fixed-dose
combinations (FDCs) and LABA/long-acting muscarinic antagonist (LAMA) FDCs are …

Background: Triple fixed-dose combination (FDC) therapy is recommended in severe
chronic obstructive pulmonary disease (COPD) patients experiencing frequent …

Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …

There are more single inhaler device triple therapy available for COPD patients now.
However, the effect of long-term triple therapy fixed dose combination (FDC) on mortality …

We read with great interest the meta-analysis recently published in the European
Respiratory Journal by Yang et al.[1] concerning the risk of major adverse cardiovascular …